Seqirus news releases
Combination nasal spray Ryaltris® (olopatadine hydrochloride and mometasone furoate) now approved for Australian children aged six years and older with hay fever or other year-round allergies
• Australia is the first major country to approve Ryaltris for use in patients six years and older, after first receiving approval for 12 years and older in 2019.1
• More than 4.6 million Australians are affected by hay fever, with up to 18% of children affected by 11 years of age.2,3
• Children with hay fever may experience irritability, distraction, fatigue, embarrassment and increased days off school, making them more likely to have poorer grades than other students.4
Cell-based Flucelvax® Quad influenza vaccine now approved for Australian children aged two years and older
• Flucelvax® Quad, Australia’s first and only cell-based influenza vaccine is now approved for children aged two years and older.1
• Flucelvax® Quad was first available in Australia in 2021 and now the TGA has approved its extended use in children down to two years for the 2022 influenza season.1
• Cell-based technology represents a significant innovation in influenza vaccine manufacturing.2
• More than 100 million doses of Flucelvax Quad® have been distributed worldwide.3
PNG Snakebite Partnership with Australia to continue to help save lives
A unique partnership between Australia and Papua New Guinea (PNG) to donate antivenoms and help save the lives of people bitten or stung by venomous snakes and marine creatures has been extended for a further two years, 2021-2023.
Don’t forget about flu – with winter approaching, flu vaccination numbers still low
• Flu vaccination rates are significantly lower than last year - fewer than one in two Australians working with patients have had their flu vaccine in 2021 – compared with almost more than double that number this time last year (47.6% vs 88.6%)
• The Australian Government recommends flu vaccination for everyone aged six months and older
• Every flu season is different – and it is hard to predict what will happen each season
CSL Dispatches First Australian Made Doses of the AstraZeneca COVID-19 Vaccine
CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling.
LOCAL MANUFACTURING OF COVID-19 VACCINE REACHES FINAL STAGES
CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards the end of March, subject to approval by the Therapeutic Goods Administration (TGA).
Ahead of a summer at home, a knowledge gap could leave Aussies underprepared to deal with bites & stings from venomous creatures
• With holidays at home in Australia this year, a new consumer survey reveals an underpreparedness to deal with potentially deadly bites and stings from venomous creatures
• Despite some experts saying snake encounters are increasing1,2, less than half of respondents could identify the correct first aid procedures for a snake bite3
• Only 27% said that they would always pack a first aid kit when going to the bush or beach, despite half indicating they have been bitten or stung and/or witnessed venomous bites and stings firsthand
• 41% could not recall ever receiving training on first aid for venomous bites and stings
Seqirus Will Build World-class, Next-generation $800m Influenza Vaccine Manufacturing Facility in Australia
CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia
CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful.
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
Additional flu vaccine supplies rolling out across Australia
Seqirus Australia is pleased to confirm that additional supplies of flu vaccinations have started to roll out across the country – with around one million doses expected to be rolled out in the next three weeks, ahead of the peak influenza months.
Seqirus to supply additional flu vaccines
Local flu vaccine manufacturer Seqirus will go back into production to supply Australians approximately two million additional flu vaccines for the 2020 flu season.
Update - PRODUCT DEFECT CORRECTION - PALEXIA® SR 100mg
In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 986P01.
PRODUCT DEFECT CORRECTION - PALEXIA® SR 100mg
In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 985P01.
Seqirus and Richter sign a license agreement for the commercialisation of a novel treatment for schizophrenia in Australia and New Zealand
Seqirus Pty Ltd (Seqirus) and Gedeon Richter Plc (Richter) today announced the signing of an exclusive license agreement to commercialise a novel antipsychotic in Australia and New Zealand.
New PNG Snakebite Project to Improve Access to Antivenoms
The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.
Australians unprepared for potential dangers of venomous creatures this summer
Seqirus launches #NoStingsSummer campaign encouraging Aussies to take care and watch out for bites and stings this summer
Seqirus launches first over-the-counter offering, Nervoderm®
Seqirus has entered the over-the-counter market for the first time with a new Schedule 2, medicated patch, Nervoderm®.